Page 2 - Vascular Access News Today

Covalon Technologies Ltd. (the "Company" or "Covalon") , an advanced medical technologies company, today proudly announced the publication of an article in the British Journal of Nursing (BJN), titled "Guarding the Central Venous Access Device: A New...

Although the primary outcome was not statistically different between a liberal and more restrictive transfusion strategy, secondary results suggest some advantages for the liberal approach.

For adults with early-stage chronic kidney disease (CKD), a proprietary formula performed well in stratifying risk of progression to more severe kidney dysfunction and of increased healthcare needs.

The global vascular closure device market is growing at a CAGR of 7.1% from 2022 to 2030.Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- A vascular closure device is a piece of collagen (a fibrous protein found in skin, connective tissue, and bone), a metallic clip, or a suture designed to close the small puncture produced in an artery following an angiography. According to our new research study on “Vascular Closure Device Market Size and Forecasts (2020 - 2030), Global and Regional Share...

Operator: Good afternoon. And welcome to the ICU Medical Inc. Third Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note, this event is being recorded.

Operator: Good morning, ladies and gentlemen, and welcome to the Teleflex Third Quarter 2023 Earnings Conference Call. At this time, all participants have been placed in a listen-only mode.

Access Vascular Inc. (AVI) closed a $22 million series C funding round that it plans to use principally to increase production capacity for its Mimix hydrophilic biomaterial vascular access devices. The company’s catheters are designed to evade identification as foreign bodies, reduce bacterial adhesion and eliminate catheter-related thrombus development.

Calculator uses readily available clinical factors and will soon be freely accessible.

The US Food and Drug Administration has approved Ardelyxs drug to treat high phosphate levels in patients with chronic kidney disease, the company said, more than 2 years after it was initially rejected.

The Bethlehem-based company is focusing on training and technology to provide equality in how patients receive "peripheral vascular access," which is treatment via an intravenous catheter that sends medicine directly